UCB stock: Barclays keeps Hold rating and EUR 260.00 target for UCB stock

Published on 10/20/2026 at 16:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

BIMZELX sales reached EUR 1.52 billion in the first half of 2026. UCB stock costs EUR 217.30 on October 20, 2026, below its 52-week high of EUR 289.50.

Analyst target and sales

Barclays maintained a Hold rating with a EUR 260.00 target on October 3, 2026.
BIMZELX sales reached EUR 1.52 billion in the first half of 2026.
UCB stock costs EUR 217.30 at Lang & Schwarz on October 20, 2026, 24.93 percent below the 52-week high.
The company trades at a P/E ratio of 18.77 and has a 1.00 percent dividend yield.

Pop-Art-Comic eines Wissenschaftlers mit leuchtendem Reagenzglas im Labor, bunte Halbtonpunkte — UCB S.A., ISIN BE0003739530, präsentiert als farbenfrohe Pop-Art-Comic-Szene mit begeistertem Wissenschaftler im Labor, Illustration mit AI erstellt.

UCB (ISIN BE0003739530) has a EUR 260.00 price target from Barclays, which maintained its Hold rating in a report dated October 3, 2026, according to The Globe and Mail. The target is 19.65 percent above the EUR 217.30 price at Lang & Schwarz on October 20, 2026 at 4:08 p.m. CEST.

BIMZELX leads the sales mix

UCB's commercial portfolio is led by BIMZELX, whose sales reached EUR 1.52 billion in the first half of 2026. The company also reported EUR 954.00 million from CIMZIA, EUR 327.00 million from BRIVIACT and EUR 239.00 million from FINTEPLA for the same period on its UCB investor page.

The product mix matters because the leading growth asset is already larger than several established medicines. UCB's investor materials also list BIMZELX peak sales guidance above EUR 7.00 billion, creating a measurable gap between first-half sales and the longer-term commercial ambition.

Stock stays below its yearly high

The EUR 217.30 Lang & Schwarz price stands within a 52-week range of EUR 197.45 to EUR 289.50. It is 24.93 percent below the high and 10.05 percent above the low, while the latest quoted market capitalization is EUR 41.5 billion.

MarketScreener identifies UCB's primary listing as Euronext Brussels and reported that the US Food and Drug Administration approved an auto-injector version of Zilbrysq on October 16, 2026. The company said the new device is expected to reach the market in the first quarter of 2027, according to MarketScreener.

Valuation leaves room for debate

UCB carries a P/E ratio of 18.77 and a trailing dividend yield of 1.00 percent. The next visible development window is the company's stated first-quarter 2027 commercialization plan, while pipeline milestones include fourth-quarter 2026 or first-half 2027 results for STACCATO alprazolam, as listed by UCB.

The price frame remains wide

For investors, the key tension is between a 24.93 percent gap to the 52-week high and Barclays' EUR 260.00 target. The stock's valuation therefore sits between a broad historical trading range and an analyst target that is 19.65 percent above the latest euro quote.

UCB was trading at EUR 217.30 at Lang & Schwarz on October 20, 2026 at 4:08 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of UCB stock.